London life sciences receives multimillion investment in research space and innovation

More than £500m in financing and investment has been announced for London's science, technology and innovation sectors, with new funding for specialist laboratory facilities and projects aimed at translating research into commercial applications.
The announcements, made during London Life Sciences Week, include a £147m commitment from the National Wealth Fund towards the development of One North Quay at Canary Wharf, alongside £22m from the Mayor of London for three innovation projects spanning healthcare and quantum technology.
The National Wealth Fund is providing £147m in debt financing towards One North Quay, forming part of a £368.5m package alongside Barclays and Emirates NBD. It is the Fund's first investment in the life sciences sector.
Being developed by CWG and Kadans Science Partner, the 23-storey building will provide around 570,000 sq ft of flexible laboratory and workspace for established businesses and growing SMEs. The project is intended to address a shortage of specialist facilities for companies developing and commercialising new technologies.
The financing will support the continued development and fit-out of the building, which is expected to be completed in early 2028. The project is also forecast to support around 440 full-time equivalent jobs during its peak construction year.
Oliver Holbourn, CEO of the National Wealth Fund, said: “The UK is home to world-leading science and innovation, and businesses need the right infrastructure if they are to translate that innovation into economic growth. The National Wealth Fund's financing for One North Quay, our first deal in the life sciences sector, will help provide the high-quality, specialist space businesses need to start, grow and scale here in the UK.”
Separately, Mayor of London Sadiq Khan has announced £22m for three projects through the Local Innovation Partnerships Fund (LIPF), part of a wider UK Research and Innovation (UKRI) programme investing up to £500m in high-potential innovation clusters across the UK.
The three London projects will receive more than £98m in additional match funding, including pledged contributions, taking the combined investment identified to over £120m. London's total LIPF allocation is £30m, with the remaining funding to be distributed in due course.
Two of the projects have a direct healthcare focus. A King's College London-led partnership with the BioInnovation Institute will receive £5m to help translate cardiometabolic research into new businesses developing treatments and medical technologies, including approaches to earlier detection of heart disease.
A further £5m will support PHIX London, led by UCLPartners in collaboration with NHS and private healthcare providers in the Harley Street Health District. The initiative aims to give businesses opportunities to test and scale healthcare technologies, including tools for detecting and monitoring high blood pressure and irregular heart rhythms.
The remaining £12m will support the London Quantum Cluster, led by UCL, Imperial College London and King's College London. The initiative aims to help high-growth companies test technologies, attract investment and develop applications across sectors including healthcare, transport, finance, energy and defence. Potential healthcare applications include the development of new medicines.
Professor Geraint Rees, UCL vice-provost for research, innovation and global engagement, said the investment would connect university research more closely with industry and investors, helping quantum technologies move beyond the laboratory and towards commercial application.
Max Stanyard, healthcare and life sciences senior analyst at RSM UK, said public investment could help unlock additional private capital, addressing one of the sector's persistent challenges: access to the funding needed for companies to commercialise and scale their technologies in the UK.
Pic: Alev Takil




